MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds
(expenses) from an...
$1,625K
Proceeds from exercise of
stock options
$58K
Proceeds from maturities
of short-term...
$13,760K
Net cash provided by
(used in) financing...
$1,685K
Net cash provided by
investing activities
$1,228K
Canceled cashflow
$12,532K
Net increase
(decrease) in cash and cash...
$303K
Canceled cashflow
$2,610K
Stock option
compensation to employees and...
$768K
Amortization of discount on
held-to-maturity securities
-$47K
Stock options issued
to consultants
$28K
Amortization of operating
lease right-of-use...
$10K
Disbursements to acquire
short-term investments
$12,532K
Net cash used in
operating activities
-$2,610K
Canceled cashflow
$853K
Interest income
$131K
Net loss
-$2,585K
Accrued expenses
-$715K
Canceled cashflow
$131K
Prepaid expenses and
other current assets
$135K
Accounts payable
-$17K
Operating lease liability
-$11K
Loss from operations
-$2,716K
Total operating costs
and expenses
$2,716K
General and
administrative expenses
$1,614K
Research and development
expenses
$1,102K
Back
Back
Cash Flow
source: myfinsight.com
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)